Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 13/20 | 0.74 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | PLEC | Q15149 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1093926 | 0.91 | APP (0.60) | APPCYP1A2MEN1POLBKMT2A | |
| SCHEMBL6663297 | 0.88 | APP (0.67) | APPCYP1A2MEN1USP2POLB | |
| SCHEMBL8066 | 0.86 | APP (1.00) | APPCYP1A2MEN1USP2POLB | |
| Ammonia Solution, Strong SCHEMBL29419058 | 0.85 | APP (0.97) | APPCYP1A2MEN1USP2POLB | |
| SCHEMBL1095367 | 0.85 | APP (0.97) | APPCYP1A2MEN1USP2POLB | |
| SCHEMBL7113427 | 0.85 | APP (0.97) | APPCYP1A2MEN1USP2POLB | |
| SCHEMBL29456578 | 0.85 | APP (0.97) | APPCYP1A2MEN1USP2POLB | |
| Ether SCHEMBL1094032 | 0.84 | APP (0.80) | APPCYP1A2MEN1USP2POLB | |
| Methoxymethane SCHEMBL2784008 | 0.84 | APP (0.89) | APPCYP1A2MEN1USP2POLB | |
| Benzoic Acid SCHEMBL21043906 | 0.83 | APP (0.78) | APPCYP1A2MEN1USP2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 354 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606625-B2 | Antibody binding specifically to B7—H3 and use thereof | Y-Biologics Inc. (KR) | 2026-04-21 | — | — | US | disclosed |
| US-20260072014-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEUROLOGICAL DISEASES COMPRISING HIGHLY POTENT STEM CELLS EXPRESSING TIMP-1, MCP-1, GROa, AND IL-6, AND METHOD FOR SELECTING HIGHLY POTENT STEM CELLS | MEDINNO INC (KR) | 2026-03-12 | — | — | US | disclosed |
| US-20260028418-A1 | ANTI-HER2 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND CHIMERIC ANTIGEN RECEPTOR COMPRISING SAME | GC CELL CORP (KR) | 2026-01-29 | — | — | US | disclosed |
| US-12473366-B2 | Anti-TIE2 antibody and use thereof | PHARMABCINE INC. (KR) | 2025-11-18 | — | — | US | disclosed |
| EP-4640850-A2 | METHOD FOR ASSESSING PROGNOSIS OR RISK STRATIFICATION OF LIVER CANCER BY USING CPG METHYLATION VARIATION IN GENE | Lepidyne Co., Ltd. (KR) | 2025-10-29 | — | — | EP | disclosed |
| EP-4640710-A1 | MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO CLAUDIN-18.2 AND USE THEREOF | Y-Biologics Inc. (KR) | 2025-10-29 | — | — | EP | disclosed |
| US-12448436-B2 | Antibody specifically binding to GRP94 or antigen-binding fragment thereof, and uses thereof | KOOKMIN UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION (KR) | 2025-10-21 | — | — | US | disclosed |
| US-12410261-B2 | Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same | GC Cell Corporation (KR) | 2025-09-09 | — | — | US | disclosed |
| US-12371736-B2 | TD probe and its uses | SEEGENE, INC. (KR) | 2025-07-29 | — | — | US | disclosed |
| CN-119895261-A | Pharmaceutical composition for preventing or treating nervous system diseases comprising high-efficiency stem cells expressing TIMP-1, MCP-1, GROα and IL-6, and method for selecting high-efficiency stem cells | 美迪因诺医疗创新科技有限公司 | 2025-04-25 | — | — | CN | disclosed |
| EP-1210342-A1 | THE USE OF FLUORESCEIN ARYL ETHERS IN HIGH THROUGHPUT CYTOCHROME P450 INHIBITION ASSAYS | GENTEST CORPORATION (US) | 2002-06-05 | — | — | EP | disclosed |
| US-20020045620-A1 | Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis in mammals | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2002-04-18 | — | — | US | disclosed |
| US-20010056183-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | TEXAS BIOTECHNOLOGY CORPORATION | 2001-12-27 | — | — | US | disclosed |
| EP-1147216-A1 | RESORUFIN DERIVATIVES AS SUBSTRATES FOR CYP3A4 | SMITHKLINE BEECHAM PLC (GB) | 2001-10-24 | — | — | EP | disclosed |
| EP-1140888-A1 | OPTICAL MOLECULAR SENSORS FOR CYTOCHROME P450 ACTIVITY | Aurora Biosciences Corporation (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001049685-A2 | SULFONAMIDES AND DERIVATIVES THEREOF THAT MODULATE THE ACTIVITY OF ENDOTHELIN | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-07-12 | — | — | WO | disclosed |
| WO-2001014361-A1 | THE USE OF FLUORESCEIN ARYL ETHERS IN HIGH THROUGHPUT CYTOCHROME P450 INHIBITION ASSAYS | GENTEST CORPORATION (US) | 2001-03-01 | — | — | WO | disclosed |
| US-6143492-A | COMPOUND USEFUL AS AN OPTICAL PROBE; DRUG SCREENING | AURORA BIOSCIENCES CORPORATION (US) | 2000-11-07 | — | — | US | disclosed |
| WO-2000044933-A1 | RESORUFIN DERIVATIVES AS SUBSTRATES FOR CYP3A4 | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000035900-A1 | OPTICAL MOLECULAR SENSORS FOR CYTOCHROME P450 ACTIVITY | AURORA BIOSCIENCES CORPORATION (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606625-B2 | Antibody binding specifically to B7—H3 and use thereof | IGSF11, CD274, TNFRSF9 | APP 2915/4885CYP1A2 3663/4885MEN1 1512/4885 |
| US-20260028418-A1 | ANTI-HER2 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND CHIMERIC ANTIGEN RECEPTOR COMPRISING SAME | IGSF11, BCR, PDCD1LG2 | APP 3039/4885CYP1A2 4592/4885MEN1 4357/4885 |
| US-20020045620-A1 | Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis in mammals | LIPA, PNLIP, PCSK9 | APP 2077/4885CYP1A2 39/4885MEN1 4579/4885 |
| US-20260072014-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF NEUROLOGICAL DISEASES COMPRISING HIGHLY POTENT STEM CELLS EXPRESSING TIMP-1, MCP-1, GROa, AND IL-6, AND METHOD FOR SELECTING HIGHLY POTENT STEM CELLS | IL6, IL1A, CCR6 | APP 73/4885CYP1A2 2423/4885MEN1 3008/4885 |
| US-20010056183-A1 | Sulfonamides and derivatives thereof that modulate the activity of endothelin | EDNRA, EDNRB, ECE1 | APP 2352/4885CYP1A2 3756/4885MEN1 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.